Scynexis Stock Price, News & Analysis

SCYNEXIS reported successful results from the Phase 3 CANDLE study for ibrexafungerp, the only oral fungicidal treatment for vaginal yeast infections. The study showed 65.4% of patients treated with ibrexafungerp had clinical success at 24 weeks, surpassing the 53.1% success rate of the placebo group. The company plans to submit a supplemental New Drug Application (sNDA) for BREXAFEMME for preventing recurrent vaginal yeast infections in the first half of 2022, with anticipated FDA approval by year-end. Ibrexafungerp has potential benefits for patients not responding to fluconazole.

SCYNEXIS, Inc. (NASDAQ: SCYX) has granted stock options and Restricted Stock Units (RSUs) to five new employees, totaling 41,000 stock options at an exercise price of $4.90 and 16,000 RSUs. These grants serve as inducements for accepting employment offers. The stock options vest over four years, with a one-year cliff, while RSUs vest over two years. SCYNEXIS is focused on developing innovative antifungal medicines, including its lead product, ibrexafungerp, recently approved by the FDA for treating fungal infections.

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology firm, announced that CEO Marco Taglietti will present at two virtual investor conferences in January 2022. The events are the LifeSci Partners 11th Annual Corporate Access Event on January 7 at 10:00 a.m. ET and the H.C. Wainwright Bioconnect 2022 Virtual Healthcare Conference from January 10-13, featuring a corporate update webcast. SCYNEXIS is focused on developing innovative treatments for drug-resistant infections, including its lead asset, ibrexafungerp, approved by the FDA on June 1, 2021.

SCYNEXIS, Inc. (NASDAQ: SCYX) announced the exercise of warrants for 3.37 million shares, gaining approximately $21.1 million. This follows an earlier $7.9 million received in December. The exercised warrants were part of Series 1 from a December 2020 financing. SCYNEXIS aims to bolster its financial position to support the commercialization of its first product, BREXAFEMME® (ibrexafungerp), approved by the FDA on June 1, 2021, alongside ongoing clinical trials targeting invasive fungal infections.

SCYNEXIS, Inc. has announced that its innovative antifungal treatment, BREXAFEMME (ibrexafungerp tablets), is now covered for over 45% of commercially insured patients in the U.S. This first-in-class treatment for vulvovaginal candidiasis (VVC) is the first new antifungal class approved by the FDA in more than 20 years. The coverage expansion is expected to enhance patient access, as it meets a significant unmet need in managing yeast infections, particularly those resistant to standard treatments.

SCYNEXIS, Inc. (NASDAQ: SCYX) has received orphan medicinal product designation from the EMA for ibrexafungerp to treat invasive candidiasis, granting 10 years of EU market exclusivity. The company also secured new U.S. and European patents extending lifecycle protection until 2038. The recent initiation of a global Phase 3 study for ibrexafungerp highlights its potential as an oral step-down therapy for invasive candidiasis. Ibrexafungerp is positioned as a significant treatment option against drug-resistant infections.

SCYNEXIS is launching a global Phase 3 study to assess the effectiveness of oral ibrexafungerp as a step-down treatment for invasive candidiasis (IC) and candidemia. This study aims to establish ibrexafungerp as the first non-azole oral option for IC caused by azole-resistant Candida species, which account for approximately 35,000 cases annually in the U.S. The study involves around 220 patients and compares ibrexafungerp to oral fluconazole following IV echinocandin therapy. The primary endpoint is 30-day all-cause mortality.

SCYNEXIS (NASDAQ: SCYX) announced the grant of stock options to two new employees for a total of 5,200 shares at an exercise price of $7.38 per share, which matches the closing price on November 30, 2021. These options are part of SCYNEXIS' inducement strategy under the 2015 Inducement Award Plan, designed to attract new talent. Each option has a ten-year term, with vesting set at one-fourth on the one-year anniversary and the remainder in equal monthly installments thereafter.

SCYNEXIS, Inc. (NASDAQ: SCYX) announced the exercise of warrants for 1.2 million shares by major stockholders, generating approximately $7.9 million. The warrants were part of a financing round from December 2019, with the remaining 3.2 million shares expiring unexercised. CEO Marco Taglietti highlighted this as a vote of confidence in the company's future, particularly following the launch of SCYNEXIS's first U.S. commercial product, BREXAFEMME, and ongoing clinical development for treating serious fungal infections.